▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #642 by analyst upside · 2026-09-27
CAMP
CAMP4 THERAPEUTICS CORPORATION
Healthcare · Market Cap $246M · P/E 0x
ANALYST PRICE TARGET
+153.0%
implied upside to consensus target
Current Price $3.92
Consensus Target $9.92
Bull Target $15.0
Bear Target $6.5
Analysts Covering 6
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
4
Hold
0
Sell
0
52-Week Low $2.85
52-Week High $7.75
YTD Return -34.7%
FUNDAMENTALS
Market Cap $246M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.31
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $4M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $2.85
52-Week High $7.75
Current Price $3.92
Bear Target $6.5
Bull Target $15.0
● Now $3.92 ● Target $9.92
TRADING DATA
Avg Volume 240K
YTD Return -34.7%
Analyst Count 6
Consensus Buy
Upside to Target +153.0%
Last Updated 2026-09-27

ANALYST SUMMARY

CAMP4 THERAPEUTICS CORPORATION (CAMP) is currently trading at $3.92 with a Wall Street consensus price target of $9.92, implying potential upside of 153.0% over the next 12 months. 6 analysts currently cover CAMP, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $15.0, while the most cautious has a target of $6.5.

CAMP operates in the Healthcare sector with a market capitalisation of $246M. The stock is down 34.7% year-to-date and is currently trading near the lower end of its 52-week range of $2.85 – $7.75.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

CGEN +93.3%
Compugen Ltd.
$225M · P/E 6.3x · Buy
AGEN +208.4%
Agenus Inc.
$386M · P/E 2.8x · Buy
ELMD +74.0%
Electromed, Inc.
$233M · P/E 21.4x · Buy
WW +97.4%
WW International, Inc.
$144M · P/E 1.6x · Hold
ORMP +48.0%
Oramed Pharmaceuticals Inc.
$197M · P/E 1.1x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for CAMP, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Piper Sandler reit
Overweight → Overweight 2026-08-14 14% win rate (7 calls)
JP Morgan ↑ Upgrade
Neutral → Overweight 2026-06-16 43% win rate (7 calls)
Chardan Capital ● Initiated
Buy 2026-06-10 33% win rate (6 calls)
Rodman & Renshaw ● Initiated
Buy 2026-04-14 29% win rate (7 calls)
Leerink Partners - Reiterated
Outperform → Outperform 2026-04-02 29% win rate (7 calls)
Cantor Fitzgerald ● Initiated
Overweight 2025-10-02 40% win rate (10 calls)
JP Morgan ↓ Downgrade
Overweight → Neutral 2025-09-16 43% win rate (7 calls)
Piper Sandler - Reiterated
Overweight → Overweight 2025-09-15 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
42
out of 100
Coverage depth
15/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →